VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

PrV-PCV2-ORF2
Vaccine Information
  • Vaccine Name: PrV-PCV2-ORF2
  • Target Pathogen: Porcine circovirus 2
  • Target Disease: Postweaning multisystemic wasting syndrome
  • Vaccine Ontology ID: VO_0004699
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • ORF2 gene engineering:
    • Type: Recombinant vector construction
    • Description: PCV2 ORF2 gene was inserted into vector pG to produce the recombinant PRV vector pGO; the genome of PRV attenuated vaccine and the transfer plasmid pGO were transfected by using Lipofectamine 2000 Reagent into swine testis cells for homologous recombination to obtain the recombinant PRV (Chao et al., 2014).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: PCV2 ORF2 gene was inserted into vector pG to produce the recombinant PRV vector pGO (Chao et al., 2014).
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Mouse Response

  • Vaccination Protocol: Six week odl mice were immunized two intramuscular immunizations 4 weeks apart (Chao et al., 2014).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: Mice were then challenged with the virulent PCV2 NY strain at 8 weeks after the first immunization (Chao et al., 2014).
  • Efficacy: Challenge experiments show that the recombinant virus and PCV2 inactivated vaccine could both protect the mice against PCV2 challenge, suggesting that the recombinant virus can be an excellent potential vaccine (Chao et al., 2014).
References
Chao et al., 2014: Chao A, Fu P, Guo X, Gao X, Cui B, Chen H. [Immune efficacy in mice by recombinant pseudorabies virus PGO expressing ORF2 gene of porcine circovirus type 2]. Wei sheng wu xue bao = Acta microbiologica Sinica. 2014; 54(2); 211-217. [PubMed: 24818470].